In one of biggest pharma deals ever, Bristol-Myers Squibb to buy biotech firm for $74B
Bristol-Myers and Celgene combined will have nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and cardiovascular disease.